

## Drug Monograph

Drug Name: **Invega Hafyera™ (paliperidone palmitate) syringe**  
 Drug Class: **Central Nervous System: Antipsychotics, Atypical (2<sup>nd</sup> Generation) Depot Products**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Invega Hafyera is available in a 1,092 mg/3.5 ml syringe and a 1,560 mg/5 ml syringe. It is packaged into a kit containing the prefilled syringe and a 20G, 1.5 inch safety needle.

**Manufacturer:** Manufactured by: Janssen Pharmaceuticals, Titusville, NJ 08560.

**Indications:** Invega Hafyera is an every-six-month injection indicated for the treatment of schizophrenia in adults after they have been adequately treated with: 1) a once-monthly paliperidone palmitate extended-release injectable suspension (Invega Sustenna) for at least four months, or 2) an every-three-month paliperidone palmitate extended-release injectable suspension (Invega Trinza) for at least one three-month cycle.

**Costs:** \$11,760.28 per 1,092 mg syringe and \$17,640.05 per 1,560 mg syringe  
Wholesale Acquisition Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Atypical Antipsychotic Reference List as a reference product.

**Status Recommendation:**

<input type="checkbox"/> Clinical Edit	<input checked="" type="checkbox"/> Reference List
<input type="checkbox"/> Open Access	<input type="checkbox"/> PDL

**Type of PA Criteria:**

<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Reference
<input type="checkbox"/> No PA Required	<input checked="" type="checkbox"/> Reference

Prepared by: April Ash, PharmD  
 Date: September 29, 2021